

Otitis Media Effusion

[View the current Otitis Media Effusion InDepth page on BioPortfolio.com \(PDF\)](#)

(http://www.bioportfolio.com/indepth/Otitis_Media_Effusion.html) - Regularly Updated.

Recent Publications on Otitis Media Effusion:



- [Toll-like Receptors 2 and 4 and Their Mutations in Patients with Otitis Media and Middle Ear Effusion.](#)
*OBJECTIVES: Toll-like receptors (TLRs) detect microbial infections and...*13th May, 2009
Department of Otolaryngology, College of Medicine, Kyung Hee University,- Clin Exp Otorhinolaryngol. 2008 Dec;1(4):189-95. Epub 2008 Dec 26. ([DOI Direct Link](#))
- [\[The relationship between nasopharynx surface-active agents and otitis media effusion\]](#)
*This experiment was done with a view to exploring the etiologic mechanism...*23rd January, 2003
Department of Otolaryngology, First Affiliated Hospital, WCUMS, Chengdu- Hua Xi Yi Ke Da Xue Xue Bao. 1999 Sep;30(3):310-1, 353.

Otitis Media Effusion Patents:



- 6607725- [Conjugate vaccine for nontypeable Haemophilus influenzae](#)
- 6867342- [Drug delivery dressing having fluid control film](#)
- 6878386- [Method of treating a bacterial infection comprising amoxicillin and potassium clavulanate](#)
- 6969762- [Selected nucleotide sequences isolated from pathogenic strains of Haemophilus influenzae](#)
- 6978244- [Computer architecture and process of patient generation, evolution, and simulation for computer based testing system](#)
- 6987093- [Single dose azithromycin](#)
- 7011849- [Second release phase formulation](#)
- 7014657- [Middle-ear implant](#)
- 7024399- [Computer architecture and process of patient generation, evolution, and simulation for computer based testing system using bayesian networks as a scripting language](#)
- 7060674- [Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis](#)

- 7067493- [Single dose azithromycin](#)
- 6783773- [Composition comprising amoxicillin and potassium clavulanate](#)
- 6770080- [Mechanically registered videoscopic myringotomy/tympanostomy tube placement system](#)
- 6756057- [Amoxicillin and potassium clavulanate dosage form](#)
- 6616913- [Composition and method for treatment of otitis media](#)
- 6660299- [Modified release pharmaceutical formulation comprising amoxycillin](#)
- 6670327- [Therapeutic uses of BPI protein products in humans with otitis media with effusion](#)
- 6676930- [Composition and method for treatment of otitis media](#)
- 6676943- [Human complement C3-degrading protein from Streptococcus pneumoniae](#)
- 6689302- [Method of making an antimicrobial tympanostomy tube](#)
- 6693077- [Keratinocyte growth factor-2](#)
- 6716813- [Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis](#)
- 6726908- [Pharmaceutical formulation](#)
- 6746692- [Modified release pharmaceutical formulation comprising amoxycillin](#)
- 7078399- [Sulfhydryl rifamycins and uses thereof](#)
- 7107253- [Computer architecture and process of patient generation, evolution and simulation for computer based testing system using bayesian networks as a scripting language](#)
- 7342011- [Rifamycin analogs and uses thereof](#)
- 7413729- [Sialic acid permease system](#)
- 7452715- [Production of the lipidated form of the peptidoglycan associated lipoproteins of gram-negative bacteria](#)
- 7456161- [Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary disease](#)
- 7488726- [Rifamycin analogs and uses thereof](#)
- 7494991- [Rifamycin analogs and uses thereof](#)
- 7501131- [Haemophilus influenzae type IV pili](#)
- 7524512- [Composition and method for the prevention and relief of the symptoms of an incompetent or patulous Eustachian tube](#)
- 7547692- [Rifamycin analogs and uses thereof](#)
- 7557086- [Method and peptide for regulating cellular activity](#)
- 7338936- [Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis](#)
- 7297340- [Vaccine and method for preventing biofilm formation](#)
- 7285123- [Apparatus for treatment of middle ear fluid in the ears of infants and toddlers](#)
- 7115732- [Selected nucleotide sequences isolated from pathogenic strains of Haemophilus influenzae](#)
- 7192930- [Method and peptide for regulating cellular activity](#)
- 7220738- [Rifamycin analogs and uses thereof](#)
- 7229622- [Synthetic chimeric fimbrin peptides](#)
- 7232667- [Keratinocyte growth factor-2 polynucleotides](#)
- 7241867- [Polypeptide encoded by a nucleotide sequence of a nontypeable strain of Haemophilus influenzae genome](#)
- 7250176- [Method of treating a bacterial infection](#)
- 7268225- [Selected nucleotide sequences isolated from pathogenic strains of Haemophilus influenzae](#)
- 7271165- [Rifamycin analogs and uses thereof](#)
- 7277874- [Computer architecture and process of patient generation, evolution, and simulation using knowledge base scripting](#)
- 7569542- [Anti-microbial targeting chimeric pharmaceutical](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

